References
References
Chapter-1


13) Nägele, E., Huber, U., “Method scale-up from analytical to preparative scale with the Agilent 1100 Series purification system PS”, Agilent Technologies Application Note 5988-6979EN, 2002


37) Duncan, W., McIntyre, D., “Increasing Productivity with LC/MS Easy Access Software”, Agilent Technologies


69) (31) Application note 806, Selerity Technologies Inc.;


73) A. Premstaller et al., Genome Res. 11, 1944–1951 (2001).


References
Chapter-2


5. USP 25–NF 20, Validation of Compendial Methods Section (1225) (United States Pharmacopeal Convention, Rockville, Maryland, USA, 2002) p 2256.


11. GLP - The United Kingdom Compliance Programme (Department of Health) 1989.
16. Validation of compedial Assays-Guidelines Pharmacopeial Convention, Rockvilie, MD, 1985".
19. Poile A E & Conion R D J. Chromatogr. 204 149 -152.

254


77. "Calibration of dissolution test apparatus (USP apparatus 1 and 2) - SOP".


82. "a b [1][dead link]


85. Ocampo, Arlene et al.; Lum, Steven; Chow, Frank (2007). "Current challenges for FDA-regulated bioanalytical laboratories for human (BA/BE) studies. Part I: defining the appropriate compliance standards - application of the principles of FDA GLP and FDA GMP to bioanalytical laboratories". The


95. http://www.caa.co.uk/docs/68/in01_731.pdf


106. "International Conference on Harmonization; Draft Guidance on Specifications:

References
Chapter-3


3) "International Conference on Harmonization; Draft Guidance on Specifications:


5) Validation of compedial Assays-GuidelinesPharmacopeial Convention, Rockville, MD, 1985".


12) 5. USP 25–NF 20, Validation of Compendial Methods Section (1225) (United States Pharmacopeal Convention, Rockville, Maryland, USA, 2002) p 2256.
18) GLP - The United Kingdom Compliance Programme (Department of Health) 1989.
23) Validation of compedial Assays-Guidelines'Pharmacopeial Convention, Rockvilie, MD, 1985".
26) Poile A E & Conion R D J. Chromatogr. 204 149 -152.
27) http://www.standardbase.com for more experiments.
References
Chapter-4


16) http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm204253.htm


19) {Clopidogrel (Plavix) [package insert]. New York,NY: Bristol-Myers Squibb and Sanofi-Synthelabo; May 2002.}


Retrieved 2009-03-02.
25) "Details for Plavix".


89) Poulsen TS, Vinholt P, Mickley H, Korsholm L, Kristensen SR, Damkier P: Existence of a clinically relevant interaction between clopidogrel and HMG-


95)^ Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and


References
Chapter-5


4) Paddock, ML; Wiley, SE; Axelrod, HL; Cohen, AE; Roy, M; Abresch, EC; Capraro, D; Murphy, AN et al. (September 2007). "MitoNEET is a uniquely folded 2Fe 2S outer mitochondrial membrane protein stabilized by pioglitazone". Proc. Natl. Acad. Sci. U.S.A. 104 (36): 14342–7. doi:10.1073/pnas.0707189104. PMC 1963346. PMID 17766440.


282


References

Chapter-6


2) "Nuvigil (Armodafinil) Drug Information: Uses, Side Effects, Drug Interactions and Warnings at RxList".


4) "Cephalon Provides Clinical Update on Phase II Study of NUVIGIL as an Adjunctive Therapy in Adults with Schizophrenia,". Retrieved 2011-08-21.

5) A Drug’s Second Act: Battling Jet Lag Retrieved 2010-3-30,

6) Regulators Reject a Drug Maker’s Plan to Use Its Alertness Pill to Overcome Jet Lag Retrieved 2010-3-30.


9) Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndrome.

13) Therapeutics Vol. 1 415–432.


29) Data on manufacturer's file.


References

Chapter-7


13. ICH Q2 (R1), Validation of Analytical Procedures: Text and Methodology
   Current Step 4 version Parent Guideline dated 27 October 1994
   (Complementary Guideline on Methodology dated 6 November 1996
   incorporated in November 2005).

14. ICH Q1A (R2), Stability Testing of New Drug Substances and Products.
    International Conference on Harmonization, Current Step 4 version dated 6
    February 2003


